论文部分内容阅读
目的探讨ABCC4(ATP-binding cassette,subfamily C member 4)基因多态性rs10508022位点与ITP患者糖皮质激素疗效的相关性。方法收集我院2013年6月至2015年6月确诊的75例ITP住院患者作为病例组,其中46例糖皮质激素敏感型,29例糖皮质激素耐药型,并同期收集60例健康体检者作为对照组。采用SNa Pshot法对所有受试者进行rs10508022位点基因分型,判断其与激素治疗ITP疗效的关系。结果 rs10508022位点基因型频率分布在病例组与对照组间差异无统计学意义(P=0.15),但在ITP患者糖皮质激素敏感组和耐药组间差异有统计学意义(P=0.003),且G等位基因是ITP患者糖皮质激素耐药的风险等位基因(OR=3.17,95%CI=1.55-6.47)。结论 ABCC4基因多态性与ITP患者糖皮质激素抵抗有关,且G等位基因可能是风险基因。
Objective To investigate the relationship between polymorphism rs10508022 of ABCC4 gene and glucocorticoid in patients with ITP. Methods A total of 75 patients with ITP admitted from June 2013 to June 2015 in our hospital were selected as the case group, 46 of which were glucocorticoid-sensitive and 29 of them were resistant to glucocorticoid. Sixty healthy subjects were collected during the same period As a control group. All subjects were genotyped by SNa Pshot method for rs10508022 locus to determine their relationship with hormone therapy ITP efficacy. Results There was no significant difference in genotype distribution between rs10508022 locus and control group (P = 0.15), but there was significant difference between glucocorticoid sensitive group and resistant group in ITP patients (P = 0.003) , And the G allele was the risk allele of glucocorticoid resistance in ITP patients (OR = 3.17, 95% CI = 1.55-6.47). Conclusion ABCC4 gene polymorphism is associated with glucocorticoid resistance in patients with ITP, and G allele may be a risk gene.